Fresnel

fresnel-energy.com

The hardest problem in biopharma is picking the right target. Despite rapid biotechnological progress, up to 90% of drug candidates fail in the clinic. Poor choice of targets drives these failures through toxicity and lack of translational efficacy. This is not for lack of information: we have a wealth of genetic and genomic evidence about targets that can mitigate these risks. Genomic evidence is associated with considerable increases in program success (~3x). Notable cases include PCSK9 (cholesterol), TYK2 (autoimmune disease), and TL1A (GI disorders). Yet this information is rarely used. Datasets are isolated, of uneven quality, and not easily accessible. A recent review has shown that despite demonstrable successes, only ⅓ of active drug programs use genomic evidence, relying instead on “gut feel” and “expert opinion.” We are building a “Bloomberg for Biology,” an intuitive software product enabling founders, executives, scientists, and investors to understand the genomic.